+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Infection prevention & Control Market - Forecast (2020 - 2025)

  • ID: 3339354
  • Report
  • March 2020
  • Region: Global
  • 117 pages
  • IndustryARC
1 of 3
Infection Prevention and Control Market size is anticipated to reach $201.71 billion by 2025, growing at a CAGR of 3.7% during the forecast period 2020-2025. With Infections and Infectious Diseases taking an extraordinary turn in all countries an incorporated methodology is required to decrease the burden thereby uniting treatment of patients and health promotions. Trends towards a fundamental understanding of the study of disease transmission; risk factors that expand persistent powerlessness to disease; and the practices, techniques and medications that may bring about contamination have clearly benefited Infection Prevention and Control market.

Key Takeaways

North America region is anticipated to grasp 44.8% share during the forecast period.

The concern for cleanliness and hygienic of all workers in keeping the environment neat; prevents the workers as well as the patients from various Health Associated Infections.

Control from various types of cross-infections in hospitals and clinics also there has been a growth of Personal Protective Equipment’s market globally.

Infection Type- Segment Analysis

In 2019, Bacterial Infections segment dominated the Infection prevention and control market. The advancements in technologies, increasing of consumer wealth due to population growth coupled with growing needs of the people towards the healthcare settings will drive the market in this region. The prevalent burden of health care-associated infection is increasing significantly higher in low- and middle-income than in high-income countries, and mostly to the patients admitted to intensive care units and in neonates with weaker immune system.

Anti-Microbial Drug Type- Segment Analysis

In 2019, anti-bacterial drug segment dominated the Infection prevention and control market. The different classes of antibacterial drugs that are currently being in the market all have diverse performance profiles, but they share a common characteristic under some useful set of condition of being lethal to micro bacteria. Regardless of numerous genuine drawbacks, the different formulations that keep up their business sector development rates is evidence of the interest for antimicrobial products.

Product & Service Equipment - Segment Analysis

The Personal protective equipment segment of Infection protection and control market is anticipated to hold major share of IP&C Market followed by Disinfectants and Sterilization. With the growth in prevention and control concerns of various Health Associated Infections, Personal Protective Equipment’s accounted for 31% of the Global IP&C Market shares. To control various types of cross-infections in hospitals and clinics also there has been a growth of Personal Protective Equipment’s market globally. Demand for better quality care in hospitals and other healthcare establishments is forcing the hospitals to invest in quality medical protective wear and other accessories has also acted as a key factor in the growth of this segment.

By End-User - Segment Analysis

At the end-user, Manufacturing Units of Infection prevention and control market will continue to dominate the IP&C Market during the forecast period. The concern for cleanliness and hygienic of all workers helps in keeping the environment neat and prevent the workers as well as the patients from various Health Associated Infections.

By Geography - Segment Analysis

North America region is anticipated to grasp 44.8% share during the forecast period. With the increase in the number of death due to Antibiotic-resistant infections, by contrast it is anticipated that there will be a growth in IP&C Market in the regions of North America and Europe. With development, rising economies, changing lifestyle and emerging microbial threat in APAC region will act as major key factors for enhancement of the global IP&C Market.   

Drivers – Infection Prevention and Control Market

Increase In Incidence Of Hospital Acquired Infections (HAIS)

Hospital acquired infections (HAI) are infections that patients come across as a result of medical services intervention to treat other conditions. The increasing rate of Hospital Acquired Infection has led to the increase in the demand of the infection prevention and control products such as syringes, gloves, disinfectants, disposable needles and so on. The advent of various infectious disease testing kits, proper means of sanitation method has also provided a wide contribution towards the increasing sales of the product in the global market.

Challenges – Infection Prevention and Control Market

Low Level Of Vaccination Among Healthcare Workers

Healthcare workers play an important role in advocating seasonal influenza vaccination to their patients. Most health care workers accept that they are healthy and in this manner will get no profit from vaccination or that the danger of unfriendly occasions after vaccination exceeds the profits. On the other hand, they are basically uninformed of the proposals for yearly flu inoculation. Vaccination for health care workers can possibly profit health care experts, their patients, and their families by lessening the transmission of the microorganisms in the health care setting.

Infection Prevention and Control Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Infection Prevention and Control market. In 2019, Infection Prevention and Control market share is fragmented by the top ten players present in the market. Infection Prevention and Control market top 10 companies are Abbott, Ansell Ltd., Astra Zeneca, Medtronic, Johnson& Johnson, Kimberly-Clark, Merck& Co, Pfizer Inc., Roche, Siemens and others.

Acquisitions/Product Launches

In October 2017, Abbott’s worldwide diagnostics business, sales growth over the last three years reflected the acquisition of Alere.

On December 2017, BD completed the acquisition of Bard, a global medical technology company in the fields of vascular, urology, oncology and surgical specialty products.


Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Infection prevention & Control Market - Overview
1.1. Definitions and Scope

2. Infection prevention & Control Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography

3. Infection prevention & Control Market
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis

4. Infection prevention & Control Market Forces
4.1. Drivers
4.2. Constraints
4.3. Challenges
4.4. Porters five force model
4.4.1. Bargaining power of suppliers
4.4.2. Bargaining powers of customers
4.4.3. Threat of new entrants
4.4.4. Rivalry among existing players
4.4.5. Threat of substitutes

5. Infection prevention & Control Market -Strategic analysis
5.1. Value chain analysis
5.2. Opportunities analysis
5.3. Product life cycle
5.4. Suppliers and distributors Market Share

6. Infection prevention & Control Market – By Infections (Market Size -$Million / $Billion)
6.1. Market Size and Market Share Analysis
6.2. Application Revenue and Trend Research
6.3. Product Segment Analysis
6.3.1. Microbial infections
6.3.1.1. Bacterial infection
6.3.1.1.1. Clostridium Difficile
6.3.1.1.2. Mycobacterium tuberculosis
6.3.1.1.3. E. Coil
6.3.1.1.4. Helicobacter pylori
6.3.1.1.5. Salmonella
6.3.1.1.6. Salmonella
6.3.1.2. Viral infection
6.3.1.2.1. Ebola Virus
6.3.1.2.2. Herpes Simplex Virus
6.3.1.2.3. Human Immunodeficiency Virus (HIV)
6.3.1.2.4. Yellow Fever
6.3.1.2.5. Dengue Viruses
6.3.1.2.6. Junin Virus
6.3.1.2.7. KFD (Kyasanur Forest Virus)
6.3.1.2.6. Machupo Virus
6.3.1.2.9. Others
6.3.1.3. Fungal Infection
6.3.1.3.1. Cryptococcus Gatti
6.3.1.3.2. Aspergillis
6.3.1.3.3. Pneumocystis Pneumonia
6.3.1.3.4. Dermatophytes
6.3.1.3.5. Gungal Keratitis
6.3.1.3.6. Exserohilum
6.3.1.3.7. Cladosporium
6.3.1.3.6. Other
6.3.2. Healthcare Associated Infections
6.3.2.1. Hospital Acquired Infection
6.3.2.1.1. Central line associated bloodstream infection (CLABSI)
6.3.2.1.2. Catheter associated Urinary Tract infection
6.3.2.1.3. Surgical site infection
6.3.2.1.4. Ventilator associated Pneumonia (VAP) infection
6.3.2.2. Community acquired infection
6.3.2.2.1. Methicillin resistant Staphylococcus aureus (MRSA) infection
6.3.2.2.2. Community acquired pneumonia

7. Infection prevention & Control Market – By Antimicrobial drugs (Market Size -$Million / $Billion)
7.1. Anti-bacterial Drug
7.2. Anti-Viral Drug
7.3. Anti-fungal Drug
7.4. Vaccine

8. Infection prevention & Control Market – By Accessories and Equipment (Market Size -$Million / $Billion)
8.1. Personal Protective Equipment
8.1.1. Gloves
8.1.2. Surgical Masks & Respirators
8.1.3. Surgical Drapes & Gown
8.1.4. Surgical Foot covers
8.1.5. Medical safety Glasses
8.1.6. Others
8.2. Disinfectants
8.2.1. Hand sanitizers
8.2.2. Disinfectants wipes
8.2.3. Surface Disinfectants
8.2.4. Instrument Disinfectants
8.2.5. Environmental Disinfectants
8.2.6. Others
8.3. Sterilization
8.3.1. Medical Device Sterilization Equipment
8.3.1.1. Wet/Stream Sterilization (Autoclave)
8.3.1.1.1. Vertical Autoclave
8.3.1.1.2. Horizontal Autoclave
8.3.1.1.3. Portable Autoclave
8.3.1.2. Dry Heat Sterilization
8.3.1.3. Low Temperature Sterilization
8.3.1.3.1. In-House Steam Sterilization
8.3.1.3.2. Ethylene Oxide (EO) Sterilization
8.3.1.3.3. Gamma and eBeam Sterilization

9. Infection prevention & Control – By End Use Industry(Market Size -$Million / $Billion)
9.1. Segment type Size and Market Share Analysis
9.2. Application Revenue and Trends by type of Application
9.3. Application Segment Analysis by Type
9.3.1. End Users: By Equipment Usage
9.3.1.1. Hospitals & Clinics
9.3.1.2. Medical Laboratories
9.3.1.3. Manufacturing Units
9.3.1.3.1. Pharmaceuticals
9.3.1.3.2. Medical Devices
9.3.1.3.3. Food & Beverages
9.3.2. End users: By Drug Usage
9.3.2.1. Individuals & Patients
9.3.2.2. Nursing & Senior care Centers

10. Infection prevention & Control - By Geography (Market Size -$Million / $Billion)
10.1. Infection prevention & Control Market - North America Segment Research
10.2. North America Market Research (Million / $Billion)
10.2.1. Segment type Size and Market Size Analysis
10.2.2. Revenue and Trends
10.2.3. Application Revenue and Trends by type of Application
10.2.4. Company Revenue and Product Analysis
10.2.5. North America Product type and Application Market Size
10.2.5.1. U.S.
10.2.5.2. Canada
10.2.5.3. Mexico
10.2.5.4. Rest of North America
10.3. Infection prevention & Control - South America Segment Research
10.4. South America Market Research (Market Size -$Million / $Billion)
10.4.1. Segment type Size and Market Size Analysis
10.4.2. Revenue and Trends
10.4.3. Application Revenue and Trends by type of Application
10.4.4. Company Revenue and Product Analysis
10.4.5. South America Product type and Application Market Size
10.4.5.1. Brazil
10.4.5.2. Venezuela
10.4.5.3. Argentina
10.4.5.4. Ecuador
10.4.5.5. Peru
10.4.5.6. Colombia
10.4.5.7. Costa Rica
10.4.5.8. Rest of South America
10.5. Infection prevention & Control - Europe Segment Research
10.6. Europe Market Research (Market Size -$Million / $Billion)
10.6.1. Segment type Size and Market Size Analysis
10.6.2. Revenue and Trends
10.6.3. Application Revenue and Trends by type of Application
10.6.4. Company Revenue and Product Analysis
10.6.5. Europe Segment Product type and Application Market Size
10.6.5.1. U.K
10.6.5.2. Germany
10.6.5.3. Italy
10.6.5.4. France
10.6.5.5. Netherlands
10.6.5.6. Belgium
10.6.5.7. Spain
10.6.5.8. Denmark
10.6.5.9. Rest of Europe
10.7. Infection prevention & Control – APAC Segment Research
10.8. APAC Market Research (Market Size -$Million / $Billion)
10.8.1. Segment type Size and Market Size Analysis
10.8.2. Revenue and Trends
10.8.3. Application Revenue and Trends by type of Application
10.8.4. Company Revenue and Product Analysis
10.8.5. APAC Segment – Product type and Application Market Size
10.8.5.1. China
10.8.5.2. Australia
10.8.5.3. Japan
10.8.5.4. South Korea
10.8.5.5. India
10.8.5.6. Taiwan
10.8.5.7. Malaysia

11. Infection prevention & Control Market - Entropy
11.1. New product launches
11.2. M&A's, collaborations, JVs and partnerships

12. Infection prevention & Control Market Company Analysis
12.1. Market Share, Company Revenue, Products, M&A, Developments
12.2. ABBOTT LABORATORIES (ABBOTT DIACNOSTICS)
12.3. ALERE
12.4. ANSELL LIMITED
12.5. ASTRAZENECEA
12.6. BARD (CR) INCORPORATED
12.7. BECTON, DICKINSON AND COMPANY
12.8. BELIMED
12.9. CANTEL

12.11. Company 10 and More

13. Infection prevention & Control Market -Appendix
13.1. Abbreviations
13.2. Sources
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

Loading
LOADING...

Adroll
adroll